Cingulate Inc. (CING)
Nasdaq · Healthcare · Biotechnology
$4.75−0.21%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $69.1M
- 52-week range
- $3.16 – $11.89
- 52-week change
- +16.38%
- EPS (trailing)
- −$3.51
Fiscal year to Dec 2025
- Net income
- −$22.4M
- Diluted EPS
- −$4.44
- Free cash flow
- −$17.4M
From the company’s annual report on SEC EDGAR.
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Headquarters: Kansas City, United States · 14 employees · cingulate.com